SOURCE: Kalorama Information

Kalorama Information

February 22, 2012 15:41 ET

Rising Melanoma Cases Drive Demand for Skin Cancer Treatments

NEW YORK, NY--(Marketwire - Feb 22, 2012) - Rates of some cancers are declining, and survival rates of some cancers are increasing, but unfortunately melanoma statistics have gone in the opposition direction. According to healthcare market research publisher Kalorama Information, increasing incidence is driving demand for drugs to treat skin conditions such as melanoma. The global market for prescription dermatological products grew at a rate of 10% from 2009 to 2011, according to The Worldwide Market for Prescription Dermatological Drugs, a market research report just released by Kalorama.

Nearly 70,230 individuals in the United States -- up from 68,720 just 2 years ago -- will be diagnosed with melanoma in 2011, according to government estimates. Incidence rates for melanoma have been increasing for at least 30 years. In recent years, the increases have been most pronounced in young white women and in older white men. Melanoma is more than 10 times more common in Caucasians than in African Americans. It is slightly more common in men than in women. Overall, the lifetime risk of getting melanoma is about 2% (1 in 50) for Caucasians, 0.1% (1 in 1,000) for African Americans, and 0.5% (1 in 200) for Hispanics. The risk for each person can be affected by a number of different factors. Although the overall melanoma survival rates have improved over the past few decades, individuals with Stage III and Stage IV melanoma do not have good odds for survival. Survival in Stage III averages 35% to 50%, while Stage IV melanoma patients experience a 5% to 10% survival average.

"Given the unfortunate scourge of melanoma, demand for skin cancer treatments was sixty percent higher than other dermatological categories," said Bruce Carlson, publisher of Kalorama Information. "New treatments such as immune response modifiers, topical immunomodulators and biologics are under development and will soon enter the market."

SkyePharma is the leader in the prescription skin cancer treatment market. The company's product Solaraze is the largest selling skin cancer dermatological product in Germany in 2010. SkyePharma plans to market this product in new geographic areas in 2011, increasing its market share. Other suppliers include companies with niche products for skin cancer and companies that offer products for a variety of cancer types. Some of the companies include Leo, 3M, Allergan, Bristol-Myers Oncology, DUSA, Eisai, Valeant Pharmaceuticals International, Merck & Company, and Pfizer.

Kalorama Information's study looks at the entire prescription dermatological drug market. Notable sectors include anti-aging and photodamage, hair loss and hair removal, and psoriasis treatments. Kalorama Information's report, The Worldwide Market for Prescription Dermatological Drugs, contains more information, including breakouts of the market into segments, key trends and market shares.

About Kalorama Information
Kalorama Information, a division of, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog.

Contact Information